2Seventy Bio Inc expected to post a loss of 81 cents a share - Earnings Preview

2Seventy Bio

29/04/2024 22:19

* 2Seventy Bio Inc  TSVT.OQ   TSVT.O  is expected to show a
fall
in quarterly revenue when it reports  results on May 1
(estimated) for the period ending March 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 66.2% decrease in revenue to $14.085 million from $41.62
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for 2Seventy Bio Inc is for
a loss
of 81 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.4%
in the last three months. ​
    * Wall Street's median 12-month price target for 2Seventy
Bio Inc
is $9.50​, above​ its last closing price of $4.26. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.05       -0.99      -1.11     Missed  -12.1
 Sep. 30 2023  -1.20       -1.03      -1.00     Beat    2.8
 Jun. 30 2023  -1.09       -1.06      -0.83     Beat    22.1​
 Mar. 31 2023  -1.20       -1.19      -1.08     Beat    9.5
 ​​Dec.        -1.59       -1.61      -0.60     Beat    62.6
 31 2022                                                
 Sep. 30 2022  -1.86       -1.80      -1.76     Beat    2.5​
 Jun. 30 2022  -2.24       -2.28      -2.02     Beat    11.2
 Mar. 31 2022  -1.84       -2.05      -3.20     Missed  -56
 This summary was machine generated April 29 at 21:19 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)